Question 1: How could we best include the input of marginalized groups in our diplomacy efforts?
Question 2: The Netherlands is often referred to as a donor with courage. If the Netherlands wants to continue being such a donor, which are the (health-related) themes we should focus on?
Question 3: How can the Netherlands best align the national and international efforts regarding Global Health?
Question 4: How can the Netherlands make more effective use of its diplomatic network abroad, including embassies, permanent representations and thematic experts (such as health attachés)?
Question 5: How can the Netherlands' position within the UN (and its reputation in the field of international (human) rights) be used to advance global health objectives?
Question 6: How can we systematically link diplomatic efforts in Brussels, Geneva and New York to the benefit of coherence and greater effectiveness?
Question 2: We would encourage the Netherlands to continue to be a leader in the safe abortion space. The urgency of safe abortion cannot be overstated, particularly in light of the recent decision in the U.S. to overturn Roe v. Wade.
Question 5: The Netherlands could emphasize the connection between SRH/global health and human rights, especially as they are viewed as human rights leaders. SRH is not immediately thought of when considering human rights solutions, but if this interconnectedness was promoted, SRH-oriented organizations would be able to reach broader audiences and appear as more relevant.
Session 2: Health systems strengthening
Question 7: How can we reach everyone, especially the most marginalized people, to ensure their access to information and medical service?
Question 8: How can we make use of the specific knowledge and experience of all different sectors involved in global health? How can we also involve the private sector in meeting the people in greatest need?
Question 9: How can we promote green and sustainable health systems strengthening?
Question 10: How can we gear health systems strengthening most effectively towards better preparedness?
Question 7: To reach marginalized groups, health efforts must employ multi-pronged approaches that include both the private and public sector. The private sector can often do a better job to reduce stigma and serve groups such as youth, LGBTQ, commercial sex workers, etc. This is particularly true if/when governments are not supportive of marginalized groups.
Question 8: As stated above, the private sector plays a critical role in reaching individuals in low- and middle-income countries, particularly in development areas like sexual and reproductive health and rights. The expertise and strength of the private sector – in many countries, a vast network of highly-skilled medical practitioners, clinicians, pharmacists, and retailers – must be leveraged to meet the needs of all people.
Question 9: Investments made by the Netherlands can require commitments from partners to implement or strengthen environmental sustainability management policies. Requiring partners to consider how their programming has an environmental impact (positive or negative) can ensure partners keep “being green” at top of mind. We have already seen success with this within other agencies like Sida.
Session 4: Products and supply
Question 17: What is necessary to improve local research and production medical supplies, medicines and vaccines?
Question 18: How can the private sector contribute to the production and distributions of medical supplies, medicines and vaccines?
Question 19: How can we facilitate local production?
Question 17 / 19: While some governments and agencies have requirements that products procured with government funds must be WHO prequalified/SRA approved or be sourced from a supplier with this distinction, this restricts opportunities for local R&D and production, despite the best intentions. In the context of reproductive health, for example, consider loosening restrictions around quality-assured supply if partners can guarantee quality assurance through other means (e.g. independent, third-party laboratory testing).
Session 6: Sustainable financing
Question 22: How do we establish sustainable and innovative health financing with the strategy?
Question 23: How do we ensure best the blending of public and private funding for the Global Health Strategy?
Question 24: How do we ensure sustainable financing for the WHO and the global health architecture at large?
Question 22: Consider looking to commercially-oriented partners, including social marketing organizations that employ cross-subsidization strategies. Some organizations offer, for example, multiple product offerings, using revenues generated from the sale of products or distribution of services to offset others (i.e. revenues from higher-end condoms offsetting IUD procurement). This promotes innovation within global health offerings while centering the work around long-term sustainability.